TrialNature communications2026

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Jaume Capdevila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.